Advanced search
Publication Cover
Modern Rheumatology Volume 22, 2012 - Issue 4
Journal homepage
223
Views
15
CrossRef citations to date
0
Altmetric
Original Article

A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis

Shigeto KobayashiDepartment of Internal Medicine, Rheumatology, Juntendo Koshigaya Hospital, Juntendo University School of Medicine, 560 Fukuroyama, Koshigaya, Saitama 343-0032, JapanCorrespondence[email protected]
,
Masayoshi HarigaiTokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan
,
Neelufar MozaffarianAbbott, 200 Abbott Park Road, Abbott Park, IL 60064, USA
,
Aileen L. PanganAbbott, 200 Abbott Park Road, Abbott Park, IL 60064, USA
,
Shringi SharmaAbbott, 200 Abbott Park Road, Abbott Park, IL 60064, USA
,
L. Steven BrownAbbott, 200 Abbott Park Road, Abbott Park, IL 60064, USA
&
Nobuyuki MiyasakaTokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan
 show all
Pages 589-597 | Received 09 Aug 2011, Accepted 01 Nov 2011, Published online: 02 Jan 2014

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Mitsumasa Kishimoto, Atsuo Taniguchi, Ayako Fujishige, Shuhei Kaneko, Sibylle Haemmerle, Brian O. Porter & Shigeto Kobayashi. (2020) Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J). Modern Rheumatology 30:1, pages 132-140.
Read now
Shigeto Kobayashi, Tomoko Kashiwagi & Junko Kimura. (2019) Real-world effectiveness and safety of adalimumab for treatment of ankylosing spondylitis in Japan. Modern Rheumatology 29:6, pages 1007-1012.
Read now
Shigeto Kobayashi & Toru Yoshinari. (2017) A multicenter, open-label, long-term study of three-year infliximab administration in Japanese patients with ankylosing spondylitis. Modern Rheumatology 27:1, pages 142-149.
Read now

Articles from other publishers (12)

Kenji Kishimoto, Shuji Asai, Mochihito Suzuki, Nobunori Takahashi, Kenya Terabe, Yoshifumi Ohashi, Kyosuke Hattori, Toshihisa Kojima & Shiro Imagama. (2023) Age and symptoms at onset of ankylosing spondylitis in Japanese patients. Modern Rheumatology 33:4, pages 817-822.
Crossref
Dennis McGonagle, Sibel Z. Aydin, Helena Marzo-Ortega, Lihi Eder & Coziana Ciurtin. (2021) Hidden in plain sight: Is there a crucial role for enthesitis assessment in the treatment and monitoring of axial spondyloarthritis?. Seminars in Arthritis and Rheumatism 51:6, pages 1147-1161.
Crossref
Gerd R. Burmester, Kenneth B. Gordon, James T. Rosenbaum, Dilek Arikan, Winnie L. Lau, Peigang Li, Freddy Faccin & Remo Panaccione. (2019) Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. Advances in Therapy 37:1, pages 364-380.
Crossref
SHIGETO KOBAYASHI. (2019) Research and Activities in Juntendo During 38 Years. Juntendo Medical Journal 65:4, pages 358-367.
Crossref
Nina Wilkinson, Teresa Tsakok, Nick Dand, Karien Bloem, Michael Duckworth, David Baudry, Angela Pushpa-Rajah, Christopher E.M. Griffiths, Nick J. Reynolds, Jonathan Barker, Richard B. Warren, A. David Burden, Theo Rispens, Deborah Stocken & Catherine Smith. (2019) Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. Journal of Investigative Dermatology 139:1, pages 115-123.
Crossref
Akiyo Otsuka, Mitsuhiro Morita & Harumoto Yamada. (2015) Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab. Journal of Orthopaedic Science 20:6, pages 1070-1077.
Crossref
Sherry Rohekar, Jon Chan, Shirley M.L. Tse, Nigil Haroon, Vinod Chandran, Louis Bessette, Dianne Mosher, Cathy Flanagan, Kevin J. Keen, Karen Adams, Michael Mallinson, Carter Thorne, Proton Rahman, Dafna D. Gladman & Robert D. Inman. (2015) 2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations. The Journal of Rheumatology 42:4, pages 665-681.
Crossref
NAOTO TAMURA & KURISU TADA. (2015) Current Status of and Future Perspectives on Biologics in Rheumatic Diseases. Juntendo Medical Journal 61:6, pages 573-579.
Crossref
M. R. K. L. Lie, M. P. Peppelenbosch, R. L. West, Z. Zelinkova & C. J. van der Woude. (2014) Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment. Alimentary Pharmacology & Therapeutics 40:10, pages 1202-1208.
Crossref
Daniel J. Kingsbury, Brigitte Bader-Meunier, Gina Patel, Vipin Arora, Jasmina Kalabic & Hartmut Kupper. (2014) Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clinical Rheumatology 33:10, pages 1433-1441.
Crossref
Marietta Luz Juan-Guardela, Lisseth Fernanda Mar?n-Carrillo, Laura Ximena Kattah-Mart?nez & Daniel G. Fern?ndez-?vila. (2014) Transaminase Elevation Secondary to the Use of Adalimumab. Reumatolog?a Cl?nica (English Edition) 10:4, pages 265-266.
Crossref
Marietta Luz Juan-Guardela, Lisseth Fernanda Mar?n-Carrillo, Laura Ximena Kattah-Mart?nez & Daniel G. Fern?ndez-?vila. (2014) Elevaci?n de transaminasas secundaria a uso de adalimumab. Reumatolog?a Cl?nica 10:4, pages 265-266.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.